Las Vegas, NV -- (SBWIRE) -- 01/08/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: LinnCo LLC (NASDAQ:LNCO), Allied Nevada Gold Corp (NYSEMKT:ANV), Geron Corporation (NASDAQ:GERN), Avanir Pharmaceuticals Inc (NASDAQ:AVNR)
LinnCo LLC (NASDAQ:LNCO) opened the session at $31.32, trading in a range of $31.17 - $31.72, and closed at $31.62. The stock showed a positive performance of 1.70% in the last trading session. Linn Co, LLC (Linn Co) sole purpose is to own LINN Energy, LLC (LINN) units. LINN is focused on the development and acquisition of oil and natural gas properties, which include various producing basins within the United States. LINN’s properties are located in eight operating regions. It includes Mid-Continent, which includes properties in Oklahoma, Louisiana and the eastern portion of the Texas Panhandle; Hugoton Basin, which includes properties located primarily in Kansas and the Shallow Texas Panhandle; Green River Basin, which includes properties located in southwest Wyoming, and Permian Basin, which includes areas in west Texas and southeast New Mexico.
Will LNCO Continue To Move Higher? Find Out Here
Allied Nevada Gold Corp (NYSEMKT:ANV) traded 2.52 million shares in the last business day while the average volume of the stock remained 3.40 million shares. The 52 week range of the stock remained $3.01 - $28.83. The stock showed a negative movement of -2.54% to end at $3.83. Allied Nevada Gold Corp. (Allied Nevada) is a gold and silver producer focused on mining, development, and exploration of properties in the state of Nevada. The Company’s operating mine, the Hycroft Mine, is an open-pit gold and silver heap leach operation located 54 miles west of Winnemucca, Nevada. During the year ended December 31, 2012, the Hycroft Mine produced 136,930 ounces of gold and 794,097 ounces of silver. In addition to the Hycroft Mine,
Has ANV Found The Bottom And Ready To Gain Momentum? Find Out Here
Geron Corporation (NASDAQ:GERN) reported 2.48 million shares were exchanged during the last trade, while the average volume is about 5.41 million shares. The stock escalated 0.22% and finished the day at $4.66. The beta of the stock is recorded at 1.24 and the EPS of the stock remained -0.35. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF),
Why Should Investors Buy GERN After The Recent Gain? Just Go Here and Find Out
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) the stock decreased -1.50% and finished the session at $3.28. Traded with volume of 2.48 million shares in the prior session and the average volume of the stock remained 3.06 million shares. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA).
Will AVNR Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)